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Abstract
Background: Pathological features of Alzheimer’s disease (AD) include aggregation of amyloid beta (Aβ) and tau
protein. Macrophage migration inhibitory factor (MIF), a proinflammatory cytokine, has been implicated in the
toxicity of aggregated Aβ. It remains unclear whether MIF affects hyperphosphorylation and aggregation of tau.
Methods: The effects of MIF deficiency in tau hyperphosphorylation were examined in Mif−/− mice receiving
intracerebroventricular (ICV) injection of streptozotocin (STZ) and in APP/PS1 transgenic mice mated with
Mif−/− mice. MIF expression and astrocyte activation were evaluated in ICV-STZ mice using immunofluorescence
staining. Cultured primary astrocytes were treated with high glucose to mimic STZ function in vitro, and the
condition medium (CM) was collected. The level of tau hyperphosphorylation in neurons treated with the astrocyte
CM was determined using Western blotting.
Results: MIF deficiency attenuated tau hyperphosphorylation in mice. ICV injection of STZ increased astrocyte
activation and MIF expression in the hippocampus. MIF deficiency attenuated astrocyte activation in ICV-STZ mice.
CM from high glucose-treated WT astrocytes increased tau hyperphosphorylation in cultured primary neurons, an
effect absent from Mif−/− astrocytes and WT astrocytes treated with the MIF inhibitor ISO-1. ISO-1 had no direct
effect on tau phosphorylation in cultured primary neurons.
Conclusions: These results suggest that MIF deficiency is associated with reduced astrocyte activation and tau
hyperphosphorylation in the mouse AD models tested. Inhibition of MIF and MIF-induced astrocyte activation may
be useful in AD prevention and therapy.
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Background
Accumulating evidence suggests that neuroinflammation
contributes to tauopathy, the pathological accumulation
of tau proteins in neurodegenerative disorders such as
Alzheimer’s disease (AD) [1]. The brain cells involved in
AD-related neuroinflammation include microglia and
astrocytes. Astrocytes, the largest and most abundant neu-
roglial cells in the brain, become activated in AD and con-
tribute to a reinforced inflammatory cascade [2]. A variety
of factors, including amyloid beta (Aβ) and proinflamma-
tory cytokines, may activate astrocytes [2]. Reactive astro-
cytes in turn produce nitric oxide and proinflammatory
cytokines such as interleukin-1 (IL-1) and IL-6, which
accelerate tauopathy including formation of neurofibrillary
tangles (NFTs) [3–5]. Although these findings suggest a
possible link between neuroinflammation and tauopa-
thy, there is little evidence for a direct role of react-
ive astrocytes in the pathological accumulation of the
microtubule-associated protein tau.
Macrophage migration inhibitory factor (MIF) is a pro-
inflammatory cytokine found in many tissues and in cells
such as monocytes and macrophages [6]. MIF has mul-
tiple functions including catalytic activities [7], lymphocyte
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activation [8], glucocorticoid counter-modulation [9], and
proinflammatory regulation [10]. In addition to modulat-
ing the immune system, MIF is involved in tumorigenesis
[11]. However, the function of MIF in the brain is not
well understood. MIF is found in neurons, astrocytes,
and microglia of the hippocampus and cortex [12], and
proinflammatory stimuli significantly upregulate the
expression of neuronal MIF at both mRNA and protein
levels [13]. Clinical studies have shown a marked in-
crease in MIF concentration in the cerebral spinal fluid
(CSF) of AD patients [14]. Another piece of evidence
indicating MIF involvement in AD is the elevated ex-
pression of CD74, which is a receptor for MIF [12, 15].
MIF has also been functionally linked to the toxicity of
Aβ aggregates, which is a major constituent of AD pla-
ques [16, 17]. Despite these findings, a correlation
between MIF and tauopathy has not been established
experimentally.
Tau hyperphosphorylation is a major pathological
feature of neurodegenerative disorders such as AD
[18]. In this study, we evaluated the effects of MIF de-
ficiency in tau hyperphosphorylation using two mouse
models of AD, one involving intracerebroventricular
(ICV) injection of streptozotocin (2-deoxy-2-(3-me-
thyl-3-nitrosoureido)-D-glucopyranose; STZ) into WT
and Mif−/− mice, and the other being the APP/PS1
transgenic mice mated with Mif−/− mice. The results
have shown that MIF deficiency significantly attenu-
ated tau hyperphosphorylation in these mouse models.
Moreover, the expression of MIF in astrocytes and the
number of reactive astrocytes were markedly increased
in the AD models, whereas MIF deficiency is associ-
ated with decreased astrocyte activation in these mice.
Finally, we found that conditioned medium from acti-
vated astrocytes could stimulate tau hyperphosphoryla-
tion in neurons in a MIF-dependent manner. Based on
these findings, we postulate that MIF plays a role in
tauopathy through activation of astrocytes.
Methods
Reagents
Primary antibodies used in this study are listed in
Table 1. Dulbecco’s modified Eagle’s medium (DMEM),
neurobasal-A and B-27® supplements were purchased
from Gibco (Invitrogen, Carlsbad, CA). The BCA pro-
tein assay kit and 4,6-diamidino-2-phenylindole (DAPI)
were obtained from Beyotime Institute of Biotechnology
(Nantong, Jiangsu, China). Mouse and rabbit control IgGs
were purchased from Santa Cruz Biotechnology (Dallas,
TX). IRDye® 800CW secondary antibodies were from LI-
COR (Lincoln, NE). Other chemicals were obtained from
Sigma Chemical Company (St. Louis, MO).
Mice and treatments
The Mif−/− (MIF-KO) mice in C57BL/6 background
were prepared as reported previously [19]. All mice
were housed (four to five animals per cage) with a 12/
12 h light/dark cycle, with ad libitum access to food
and water. The housing, breeding, and animal experi-
ments were in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals,
with procedures approved by the Biological Research Eth-
ics Committee of Shanghai Jiao Tong University. Breeding
with the APP/PS1 mice were detailed in Additional file 1.
Female WT and Mif−/− mice of 3–6 months in age
were randomly divided into control and ICV-STZ (strep-
tozotocin, 2-deoxy-2-(3-methyl-3-nitrosoureido)-D-glu-
copyranose; Sigma) groups. The ICV-STZ mice were
established by intracerebroventricular injection of a single
dose of STZ [20]. Briefly, mice were anesthetized by in-
traperitoneal injection of 5 mg/ml pentobarbital sodium
(Sigma) and then restrained onto a stereotaxic appar-
atus. Each mouse received a single ICV injection of
3 mg STZ/kg body weight, which was freshly pre-
pared in normal saline, into both lateral brain ventri-
cles. The bregma coordinates used for injection were
−1.0 mm lateral, −0.3 mm posterior, and −2.5 mm below.
Table 1 Primary antibodies used in this study
Antibody Type Specificity Phosphorylation sites Reference/source
Tau5 Mono- Tau (total) Invitrogen, Carlsbad, CA, USA
Tau1 Mono- Tau (non-phos.) Millipore, Temecula, CA, USA
pS199 Poly- P-tau Ser199 Invitrogen
pT205 Poly- P-tau Thr205 Invitrogen
pS396 Poly- P-tau Ser396 Invitrogen
pS404 Poly- P-tau Ser404 Invitrogen
GFAP Poly- GFAP Proteintech, Chicago, IL, USA
GFAP−Cy3™ Mono- GFAP Sigma-Aldrich, St Louis, MO, USA
MIF Poly- MIF Abcam, Cambridge, MA, USA
Anti-β-actin Mono- β-actin Sigma
Anti-GAPDH Poly- GAPDH GoodHere Technology, Hangzhou, China
Li et al. Journal of Neuroinflammation  (2015) 12:177 Page 2 of 11
As controls, ICV-saline mice received an equal volume
of normal saline. All mice were placed on heating pads
(37 °C) until recovered from surgery. The body weight
of these mice was measured once every 7 days. Six
weeks after ICV injection, all mice were sacrificed by
decapitation and their brains removed immediately
(Fig. 1a). The hippocampi and cerebral cortices of the
mice were dissected, flash frozen in dry ice, and stored
at −80 °C for biochemical analyses later. Some brain
tissues were fixed with 4 % paraformaldehyde in 0.1 M
PBS, followed by cryoprotection in 30 % sucrose. Sagit-
tal sections of 30-μm thickness were cut using a freez-
ing sliding microtome. The sections were stored in
glycol anti-freeze solution (ethylene glycol, glycerol,
and 0.1 M PBS in 3:3:4 ratio) at −20 °C until immuno-
histochemical staining.
Western blot
Mouse brain tissue was homogenized in lysis buffer con-
taining 50 mM Tris-HCl (pH 7.4), 100 mM NaF, 2 mM
EDTA, 10 mM β-mercaptoethanol, 2 mM sodium vanad-
ate, 8.5 % sucrose, 5 μg/ml aprotinin, 100 μg/ml leupeptin,
and 5 μg/ml pepstatin. Protein concentrations were deter-
mined by using a BCA Kit according to the manufacturer’s
protocol. Tissue homogenates were separated on 10 %
SDS-PAGE, and separated samples were transferred onto
nitrocellulose membranes (Whatman Protran®). The blots
were incubated with primary antibodies and further treated
with corresponding secondary antibodies before scanning
using an Odyssey P140-CLx Infrared Imager (LI-COR Bio-
sciences, Lincoln, Nebraska). Densitometric quantification
of protein bands in Western blots was analyzed using the
TINA software (Raytest Isotopenmessgeraete GmbH,
Straubenhardt, Germany).
Immunofluorescence staining
Sections of mouse brain were permeabilized in 3 %
H2O2 and 50 % methanol in 0.05 M TBS (containing
0.05 M Tris buffer and 9 g/l NaCl) for 30 min at room
temperature, followed by blocked with blocking solu-
tion containing 5 % normal goat serum and 0.1 %
Tween-20 in Tris-buffered saline, pH 7.4 (TBS) at room
temperature for 30 min. Sections were then incubated
with primary antibodies overnight at 4 °C, rinsed with
TBS, and further treated with secondary antibodies for
1 h in the dark at room temperature. Again after three
washes in TBS, sections were stained for nuclei with
5 μg/ml DAPI for 10 min at room temperature, and
then mounted on glass slides. Fluorescent images were
taken on a laser-scanning confocal fluorescent micro-
scope (Leica TCS SP8, Leica Microsystems, Wetzlar,
Germany). The immunofluorescence intensity was quan-
tified using ImagePro Plus Software (Media Cybernetics,
Silver Spring, MD). The results were expressed as mean ±
SEM based on a minimum of five individual fields. Stu-
dent’s t test was used for statistical analysis with the Prism
software (Ver. 5, GraphPad, San Diego, CA).
Primary neuronal cultures
Neuronal cultures were established in cortices obtained
from 1-day-old Mif−/− or WT mice as described before
[21] with minor modification. In brief, cerebral cortices
Fig. 1 Schematic representation of study design and body weight change in Mif−/− mice and WT littermates. a Female mice aged 3-6 months
received intracerebroventricular (ICV) injection of either saline or 3.0 mg/kg STZ on day 0. Mice were weighed once every 7 days until day 42,
when mice were sacrificed and hippocampus, cerebral cortex and brain sections were prepared for further biochemical studies. The body weight
of WT and Mif−/− mice receiving STZ or saline was recorded and shown in (b) and (c), respectively. Each group contained 6-8 mice and the data
shown are the means ± SEM. *p < 0.05 compared with controls
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were removed from the brains of mouse pups, the
meanings and microvessels were removed, and tissues
were minced with a sterile razor blade. Tissues were
digested with 0.025 % trypsin (Sigma) and 0.01 %
DNase I (Sigma) at 37 °C for 10 min. The cell suspen-
sion was filtered through a 200 mesh sieve, and cells
were plated on poly-D-lysine (Sigma)-coated 24-well
plates at a density of 5 × 105 cells per well. Two hours
later, the DMEM medium (containing 10 % FBS, 100 U/
ml of penicillin, and 100 g/ml streptomycin sulfate) were
replaced with neurobasal medium containing 2 % B-27®
supplements for 2 days. Culture medium were changed
to neurobasal with 10 % FBS and 3 μg/ml cytosine-β-
D-arabinofuranoside (Ara-C, Sigma) in the following
2 days, and then again switched back to neurobasal
medium containing 2 % B-27® supplements. Experi-
ments were performed on days 7–8 after initiation of
the culture.
Primary astrocyte culture
Astrocyte cultures were prepared from 1-day-old Mif−/−
and WT mice as described before [22, 23]. Specifically,
separated cells were cultured in poly-D-lysine-coated
75-cm2 flasks with DMEM medium (containing 10 %
FBS, 100 U/ml penicillin, and 100 g/ml streptomycin
sulfate). The medium was replenished on day 1 and day
3. On day 7, microglia cells in the culture flasks were
shaken off at 260× rpm for 2.5 h, and the remaining as-
trocytes were maintained in DMEM with 10 % FBS
until seeding into 6-well plates. Experiments were per-
formed after one passage of the cells.
Treatment with conditioned medium of astrocytes
When astrocytes cultured in plates grew to 70–80 % con-
fluence, the culture medium was replaced with fresh
DMEM without FBS, or with the above medium contain-
ing 75 mM or 150 mM glucose. The cells were incubated
for another 12, 24, 48, and 72 h. At the end of the incuba-
tion, conditioned medium (CM) was collected and cells
were lysed in 2×SDS buffer for immunoblotting analysis.
The astrocyte CM collected at different time points was
added to the culture of neurons from Mif−/− or WT mice
for another 12, 24, and 48 h. The neuronal cell lysate was
prepared and analyzed by SDS-PAGE and Western blot-
ting as detailed above.
Statistical analyses
Data are presented as means ± SEM from at least three
experiments. One-way ANOVA followed by Newman-
Keuls test or Student’s t test was performed using the
statistic software Prism 5 (GraphPad). p < 0.05 was con-
sidered statistically significant.
Results
MIF deficiency reverses body weight decrease in ICV-STZ
mice
In this study, we used two mouse models of AD to investi-
gate the effect of MIF on tau phosphorylation. The first
model was generated by ICV injection of STZ (ICV-STZ)
[24, 25] in Mif−/− mice and WT littermates, using normal
saline as a control (ICV-saline). As STZ-induced animal
models are characterized by insulin deficiency, elevated
glucose level, and lower body weight, changes in the body
weight were monitored in these mice over a period of
42 days. Mice receiving ICV-STZ had lower body weight
compared with mice receiving saline (Fig. 1b). This result
was consistent with a previous report using rats [26]. In
the Mif−/− group, mice receiving ICV-STZ had higher
body weight than those receiving ICV-saline (Fig. 1c).
These results show that Mif deficiency reversed the de-
crease in body weight seen in ICV-STZ mice.
MIF deficiency attenuates tau hyperphosphorylation in
mice receiving ICV-STZ
To investigate whether MIF affects tau phosphorylation,
we examined the levels of total tau (using the Tau5 anti-
body), non-phosphorylated tau (using the Tau1 antibody),
and phosphorylated tau at several AD-related amino acid
positions including Ser199, Thr205, Ser396, and Ser404 in
the hippocampus and cerebral cortex of mice receiving
ICV injection of STZ. As expected, in the hippocampi of
WT ICV-STZ mice, there was an increase in tau phos-
phorylation at Ser199, Thr205, and Ser396 (Fig. 2a, c)
when compared with the ICV-saline controls. The same
comparison also identified a marked decrease in the
level of non-phosphorylated tau in WT ICV-STZ mice
(Fig. 2a, c). When normalized against total tau protein
(Tau5), an increase in tau phosohorylation at Thr205
and Ser396 was evident (Fig. 2b). In the Mif−/− mice,
however, no significant difference was observed in tau
phosphorylation at these amino acids, nor was the ex-
pression of total tau and non-phosphorylated tau pro-
teins different between the ICV-saline and ICV-STZ
groups (Fig. 2a–c). Moreover, a comparison of the ICV-
saline groups found that tau phosphorylation at Thr205
and Ser396 was reduced in the Mif−/− mice (Fig. 2a–c).
In cerebral cortex, increased tau phosphorylation was
also observed at Thr205 and Ser396 in the WT mice
receiving ICV-STZ, but tau phosphorylation at these
sites was significantly reduced in Mif−/− mice receiving
ICV-saline or ICV-STZ (Additional file 1: Figure S1).
These findings suggest that MIF is involved in basal
(saline) and induced (STZ) phosphorylation of tau in
the ICV mouse model.
In addition to immunoblotting, immunofluorescence
staining was performed to confirm increased tau phos-
phorylation at Thr205 and Ser396 and their distribution
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in the brain. Frozen brain slices were stained with primary
anti-Tau (pT205) and anti-Tau (pS396) antibodies, and
then treated with Alexa Fluor® 568 conjugated anti-rabbit
IgG (red). As shown in Fig. 3, increased red fluorescence
was observed in the CA1, CA3, and dentate gyrus (DG)
areas of hippocampus and in the cortex of ICV-STZ WT
mice, compared with WT mice receiving ICV-saline. In
contrast, no difference was observed between the STZ
and saline groups in Mif−/− mice. Similar to the results
from immunoblotting analysis, absence of MIF lowered
the baseline of phosphorylated tau at Thr205 and Ser396
in the brain slices. These results support the notion that
Fig. 2 Effect of MIF on tau hyperphosphorylation in the hippocampus. a Representative Western blots showing tau hyperphosphorylation at
S199, T205, S396, and S404 in the hippocampi of WT and Mif−/− mice receiving ICV injection of STZ or saline. The levels of non-phosphorylated
tau (Tau1) and total tau (Tau5) were also measured. Quantification of the immunoreactivity of representative Western blots, normalized against
total tau (b) and β-actin (c). *p < 0.05, **p < 0.01 compared with WT mice receiving saline
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MIF is involved in regulating tau phosphorylation in the
mouse brain.
We also used the APP/PS1 double-transgenic mouse
model to confirm MIF involvement in the regulation of
tau hyperphosphorylation. APP/PS1 transgenic mice were
mated with Mif−/− mice. Six-month-old APP/PS1+/−Mif+/+
mice exhibited significantly increased tau phosphorylation
at Ser199, Thr205, Ser396, and Ser404 when compared
with age-matched APP/PS1−/−Mif+/+ control mice
(Additional file 1: Figure S2). When mated with the
Mif−/− mice to generate APP/PS1+/−Mif−/− offspring,
tau phosphorylation at these sites was markedly atten-
uated in comparison with the APP/PS1+/−Mif+/+ mice
(Additional file 1: Figure S2).
MIF deficiency attenuates astrocyte activation in mice
receiving ICV injection of STZ
MIF is a proinflammatory cytokine that plays an import-
ant role in inflammatory response by stimulating glial
cells. It is postulated that MIF-activated glial cells may
contribute to tau phosphorylation in neurons. To test
this possibility, we first examined the expression of MIF
in WT mice that received ICV injection of saline or
STZ. Immunofluorescence staining of serial slices from
WT mouse brain with antibodies against MIF (green
fluorescence) identified a significant upregulation of MIF
in CA and DG areas of hippocampus in ICV-STZ mice
compared to mice receiving saline (Fig. 4a, b). Moreover,
it is evident that the increased MIF colocalized with neu-
rons based on the staining pattern (Fig. 4a), consistent
with a previous study [13]. To investigate the activation
of astrocytes and their distribution, we stained frozen
slices of brain tissue with CY3TM conjugated mouse
monoclonal anti-glial fibrillary acidic protein (GFAP; red
fluorescence). The expression of GFAP, a protein abun-
dant in activated astrocytes, was increased in ICV-STZ
mice. Double immunofluorescence staining showed an
increase in MIF colocalization with activated astrocytes
in the brain of ICV-STZ mice (Fig. 4a), which showed
increased GFAP expression (Fig. 4a, c). These results
suggest that ICV injection of STZ induce the expression
of MIF and the activation of astrocytes.
Fig. 3 Staining of phosphorylated tau in brain slices from WT and MIF deficient mice. a, b Frozen slices from cortex and three different regions
of hippocampus were stained for phosphorylated tau using rabbit polyclonal anti-Tau (pT205) and anti-Tau (pS396) antibodies. The sections
were further treated with Alexa Fluor 568-conjugated anti-rabbit IgG (red fluorescence) and examined under a laser-scanning confocal microscope.
Nuclei were stained with DAPI (blue). Scale bar in the upper left panes 75 μm (×200 magnification). Quantification of the level of tau phosphorylation
at pT205 (c) and pS396 (d) in each of the regions, showing differences in fluorescence intensity between WT and Mif−/− mice receiving STZ and saline.
Relative immunofluorescence was measured, and the results are presented as the means ± SEM based on five viewing fields for each region, using at
least two mice. *p < 0.05, **p < 0.01 compared with Mif+/+ mice receiving saline
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To further determine whether MIF is involve in the acti-
vation of astroyctes in the AD model, we compared WT
mice with Mif−/− mice that received ICV injection of saline
or STZ for the expression of GFAP. Frozen brain slices
from these mice were stained with the same anti-GFAP
antibody. The results showed a marked increase in GFAP
Fig. 4 Upregulation of MIF in ICV-STZ mice and colocalization with GFAP in the hippocampus. a Serial sections of WT mouse brain were stained
for MIF protein using a rabbit anti-MIF polyclonal antibody and Alexa Fluor 488-conjugated anti-rabbit IgG (green fluorescence). The sections were
subsequently stained for GFAP using a monoclonal anti-GFAP Cy3TM antibody (red fluorescence). Nuclei were stained with DAPI (blue). Images with
combined fluorescent channels are shown at ×200 (scale bar in the upper left panel 75 μm). Selected areas are enlarged by 10 times and shown
as combined as well as individual fluorescence stains. Quantification of the MIF (b) and GFAP (c) fluorescence was shown after normalization of
the green (MIF) and red (GFAP) fluorescence against the blue fluorescence (nuclei). Data shown are means ± SEM based on multiple experiments
(n = 3). *p < 0.05, **p < 0.01 compared with WT mice receiving saline
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stain (red fluorescence) in the CA1, CA3, and DG areas of
hippocampus and the cortex of WT mice that received
ICV-STZ, compared to the ICV-saline group (Additional
file 1: Figure S3A, S3B). In the Mif−/− mice, however, there
was no significant change in GFAP fluorescence between
the ICV-STZ and ICV-saline groups. These results suggest
that MIF is required for the activation of astrocytes in the
ICV-STZ mouse model.
MIF regulates tau phosphorylation through activation of
astrocytes
To determine whether MIF acts on neurons directly,
we examined the levels of tau phosphorylation in cul-
tured neurons that were exposed to MIF and the MIF
inhibitor ISO-1. None of these treatments had a signifi-
cant effect on tau phosphorylation (Additional file 1:
Figure S4A and S4B), suggesting that MIF might affect
tau phosphorylation through an indirect mechanism.
Since MIF is known to stimulate astrocyte activation, it
was postulated that MIF regulation of tau phosphoryl-
ation might be mediated through activated astrocytes.
Given that STZ injection led to astrocyte activation as well
as an increase in glucose level [24], we sought to expose
cultured primary astrocytes from WT and Mif−/− newborn
mice to high glucose (75 mM and 150 mM) to mimic the
effect of STZ injection in mice. High glucose conditions
have been used in previous studies at glucose concentra-
tions up to 150 mM, but these high concentrations are
suitable only for cultured cells [24, 27–29]. The level of
GFAP in cultured astrocytes was determined by Western
blotting and used as an indication of astrocyte activation.
As shown in Fig. 5a, the expression level of GFAP in WT
astrocytes was significantly increased after 24 and 48 h of
high glucose treatment. However, this effect was absent in
Mif−/− astrocytes (Fig. 5a, shaded bars), suggesting that
MIF plays a role in high glucose-induced activation of
astrocytes.
High glucose treatment of neurons did not alter the
level of tau phosphorylation significantly (Additional
file 1: Figure S4C), nor did it significantly alter the via-
bility of the cultured neurons and astrocytes (data not
shown). To further examine the role of astrocytes in MIF-
induced tau hyperphosphorylation, primary neurons from
WT and Mif−/− mice were cultured in the presence of CM
collected from WT and Mif−/− astrocytes exposed to high
glucose. Under this experimental condition, primary neu-
rons cultured with the CM from WT astrocytes showed
elevated tau phosphorylation (Fig. 5b), whereas those cul-
tured with CM from Mif−/− astrocytes did not (Fig. 5c).
Mif deficiency in neurons had no effect in the level of tau
phosphorylation induced by the CM from high glucose-
activated astrocytes (Fig. 5b, c).
The role for MIF in high glucose-induced astrocyte
activation was further tested using the MIF inhibitor
ISO-1. When primary astrocytes were exposed to high
glucose in the presence of ISO-1, CM collected from
the cultured astrocytes could no longer stimulate tau
phosphorylation at T205 in primary cultures of neurons
(Fig. 6). Therefore, inhibition of MIF in astrocytes dur-
ing treatment with high glucose abrogated the ability of
the CM to stimulate tau phosphorylation. Collectively,
these results suggest that MIF in astrocytes but not
neurons plays an important role in elevated tau phos-
phorylation, which involves mediators released by the
activated astrocytes.
Discussion
The majority of published studies showed that intracellular
NFTs often accompany activated astrocytes [30], suggest-
ing possible links between activated astrocytes and tau
phosphorylation. In one study, it was reported that astro-
cytes play an important role for Aβ-induced tau phosphor-
ylation in primary neurons [31]. Another study showed
that a small molecule, p75NTR ligand (LM11A-31), could
attenuate tau hyperphosphorylation and activation of as-
trocytes in APP transgenic mice [32]. However, there has
been no direct evidence for a role of astrocyte activation in
tau phosphorylation. As a result, the identity of a suspected
mediator remains obscure. The present study documents
the effect of MIF in activating astrocytes and modulating
tau phosphorylation, thereby providing novel insight into
an indirect activation mechanism.
In this study, we evaluated the effects of MIF on tau
hyperphosphorylation using two mouse models of AD.
ICV injection of STZ is one of the well-known experi-
mental models for sporadic AD [33]. We found that
ICV-STZ injection into WT mice induced tau hyper-
phosphorylation at several AD-related sites including
Ser199, Thr205, and Ser396 in the hippocampus and
cerebral cortex. This result is consistent with two pub-
lished studies that compared the ICV-STZ approach with
other mouse models of AD [24, 34]. In Mif−/− mice, no
significant difference was found in the levels of tau phos-
phorylation between the ICV-STZ and ICV-saline groups.
This finding provides first evidence for a potential role of
MIF in STZ-induced tau phosphorylation. An involve-
ment of MIF in maintaining the level of tau phosphoryl-
ation is also suggested by the observation that the baseline
of phosphorylated tau at two of the AD-related sites
(Thr205 and Ser396) was reduced in Mif−/− mice.
Results obtained from another mouse model also
support a potential role for MIF in regulating tau
phosphorylation. The APP/PS1 transgenic mice have
been widely used in studies of AD. Mutations in the
genes of amyloid precursor protein (APP) and preseni-
lins (PS1, PS2) increase the production of Aβ and
cause familial Alzheimer’s disease. The APP/PS1 trans-
genic mice were mated with the Mif−/− mice to generate
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APP/PS1/Mif−/− mice for investigation of the potential
role of MIF in tau phosphorylation. In these mice, an ele-
vation in the level of phosphorylated tau, typically seen in
the APP/PS1 mice, was attenuated in the absence of Mif.
This result provides additional evidence for a role of
MIF in tau hyperphosphorylation in the AD mouse.
The mouse strain may be useful for further studies that
will focus on the role of MIF on Aβ plaque formation
and AD progression.
Different brain cells were analyzed for their involvement
in MIF regulation of tau phosphorylation. No difference
was found in the level of tau phosphorylation in primary
cultures of neurons from either WT or Mif−/− mice. Add-
itionally, neither MIF nor the MIF inhibitor ISO-1 directly
affected tau phosphorylation at T205 in primary neurons.
Altogether, these results suggest that MIF indirectly regu-
lates tau phosphorylation through other types of cells.
Our finding that MIF increases GFAP expression suggests
that MIF activates astrocytes. Based on this observation,
we postulated that MIF regulates tau phosphorylation
through activation of astrocytes. Our experimental results
from transfer of astrocyte-conditioned medium to cul-
tured neurons suggest that the MIF-activated astrocytes
release mediator(s) that stimulate tau hyperphosphoryla-
tion in primary neurons. At present, the nature of the me-
diator(s) in the MIF-stimulated astrocyte medium remains
unclear. Potential candidates include nitric oxide and
S100B that are known to be released from astrocytes
Fig. 5 MIF regulation of tau phosphorylation through activated astrocytes. a Primary cultures of astrocytes (Ast) from WT and Mif−/− newborn
mice were treated with DMEM with or without high glucose (75 mM and 150 mM) for 12, 24, 48, and 72 h. The cell lysate was analyzed by
Western blotting for the expression of GFAP. The data are presented as densitometric values after normalization against the GAPDH level and are
shown as the means ± SEM from at least three separate experiments; *p < 0.05, **p < 0.01 scompared with cells without stimulation. For b and c,
freshly isolated neurons from WT and Mif−/− mice were cultured for 48 h with conditional medium (CM) of WT (b) and Mif−/− (c) astrocytes that
were exposed to high glucose (75 mM and 150 mM) or normal medium (c, DMEM) for 24 and 48 h. Western blotting was performed to detect
phosphorylated tau (pT205) in primary neurons. The blots were quantified by densitometry after normalization against total tau (Tau5). All data
shown are means ± SEM of multiple experiments (n ≥ 3), each in dulplicate. c Control. * and #p < 0.05, ** and ##p < 0.01 compared with medium
without high glucose
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and induce tau hyperphosphorylation in cell culture-
based experiments [5, 35]. Future studies will focus on
these mediator(s) for their involvement in MIF-stimulated
tau hyperphosphorylation through astrocytes.
Conclusions
MIF is an inflammatory cytokine with pleiotropic func-
tions in many chronic inflammatory diseases. Using two
mouse models of AD, we demonstrate that MIF plays a
role in the regulation of tau hyperphosphorylation in neu-
rons. MIF does not directly affect tau phosphorylation;
instead, MIF activates astrocytes that release mediator(s)
capable of stimulating tau hyperphosphorylation in neu-
rons. Our findings corroborate the notion that MIF may
be a potential target for therapeutic intervention of AD.
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